Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 2, 1996European Heart JournalOpen Access

Reteplase demonstrated superior early coronary artery patency rates compared with alteplase and comparable mortality and clinical benefits to streptokinase, without an increase in bleeding complications.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does reteplase improve early coronary artery patency and clinical outcomes compared to alteplase or streptokinase in patients with acute myocardial infarction?

Population

Patients with acute myocardial infarction evaluated in three large-scale clinical trials

Comparison

Reteplase (double-bolus regimen) vs Alteplase or streptokinase

Design

Review

Authors

WWW. Douglas Weaver

Discussion

Loading...

Member takes

Overview

May support reteplase for convenient AMI thrombolysis; leaves open contemporary randomized comparisons.

Structured PICO

Does reteplase improve early coronary artery patency and clinical outcomes compared to alteplase or streptokinase in patients with acute myocardial infarction?

P
Population
Patients with acute myocardial infarction evaluated in three large-scale clinical trials (RAPID 1, RAPID 2, and INJECT)
I
Intervention
Reteplase (double-bolus regimen)
C
Comparator
Alteplase (infused over 3 hours or 90 minutes) or streptokinase
O
Outcome
Early coronary artery patency rates (TIMI 3 flow) and mortality

Reteplase offers a convenient double-bolus dosing regimen with superior early coronary patency compared to alteplase and comparable clinical outcomes to streptokinase in acute myocardial infarction.

Cite This Study

W. Douglas Weaver (1996) studied this question.

synapsesocial.com/papers/6a7d0d8158b935a3e446ca86https://doi.org/10.1093/eurheartj/17.suppl_f.9
View Full Paper
Ask AI
Bookmark
Share